These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 36562592)
1. Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma. Azzi G; Tavallai M; Aushev VN; Koyen Malashevich A; Botta GP; Tejani MA; Hanna D; Krinshpun S; Malhotra M; Jurdi A; Aleshin A; Kasi PM Oncologist; 2023 Mar; 28(3):220-229. PubMed ID: 36562592 [TBL] [Abstract][Full Text] [Related]
2. Assessing Circulating Tumour DNA (ctDNA) as a Biomarker for Anal Cancer Management: A Systematic Review. Temperley HC; Fannon T; O'Sullivan NJ; O'Neill M; Mac Curtain BM; Gilham C; O'Sullivan J; O'Kane G; Mehigan BJ; O'Toole S; Larkin JO; Gallagher D; McCormick P; Kelly ME Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612815 [TBL] [Abstract][Full Text] [Related]
3. Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma. Kogo R; Manako T; Iwaya T; Nishizuka S; Hiraki H; Sasaki Y; Idogawa M; Tokino T; Koide A; Komune N; Yasumatsu R; Nakagawa T Cancer Med; 2022 Nov; 11(21):3960-3968. PubMed ID: 35352507 [TBL] [Abstract][Full Text] [Related]
4. Mutational Signature Changes in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. LaPelusa M; Cann C; Ciombor KK; Eng C Oncologist; 2024 Apr; 29(4):e475-e486. PubMed ID: 38103030 [TBL] [Abstract][Full Text] [Related]
5. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma. Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901 [TBL] [Abstract][Full Text] [Related]
6. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer. Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407 [TBL] [Abstract][Full Text] [Related]
7. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Eroglu Z; Krinshpun S; Kalashnikova E; Sudhaman S; Ozturk Topcu T; Nichols M; Martin J; Bui KM; Palsuledesai CC; Malhotra M; Olshan P; Markowitz J; Khushalani NI; Tarhini AA; Messina JL; Aleshin A Cancer; 2023 Jun; 129(11):1723-1734. PubMed ID: 36869646 [TBL] [Abstract][Full Text] [Related]
8. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments. Oh Y; Yoon SM; Lee J; Park JH; Lee S; Hong T; Chung LI; Sudhaman S; Riddell T; Palsuledesai CC; Krainock M; Liu MC; Chae YK Thorac Cancer; 2024 May; 15(13):1095-1102. PubMed ID: 38558374 [TBL] [Abstract][Full Text] [Related]
9. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort. Henriksen TV; Demuth C; Frydendahl A; Nors J; Nesic M; Rasmussen MH; Reinert T; Larsen OH; Jaensch C; Løve US; Andersen PV; Kolbro T; Thorlacius-Ussing O; Monti A; Gögenur M; Kildsig J; Bondeven P; Schlesinger NH; Iversen LH; Gotschalck KA; Andersen CL Ann Oncol; 2024 Feb; 35(2):229-239. PubMed ID: 37992872 [TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis. Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376 [TBL] [Abstract][Full Text] [Related]
11. Detection of circulating tumor DNA by tumor-informed whole-genome sequencing enables prediction of recurrence in stage III colorectal cancer patients. Frydendahl A; Nors J; Rasmussen MH; Henriksen TV; Nesic M; Reinert T; Afterman D; Lauterman T; Kuzman M; Gonzalez S; Glavas D; Smadback J; Maloney D; Levativ J; Yahalom M; Ptashkin R; Tavassoly I; Donenhirsh Z; White E; Kandasamy R; Alon U; Nordentoft I; Lindskrog SV; Dyrskjøt L; Jaensch C; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Zviran A; Oklander B; Andersen CL Eur J Cancer; 2024 Nov; 211():114314. PubMed ID: 39316995 [TBL] [Abstract][Full Text] [Related]
12. Noninvasive diagnosis and monitoring of mutations by deep sequencing of circulating tumor DNA in esophageal squamous cell carcinoma. Luo H; Li H; Hu Z; Wu H; Liu C; Li Y; Zhang X; Lin P; Hou Q; Ding G; Wang Y; Li S; Wei D; Qiu F; Li Y; Wu S Biochem Biophys Res Commun; 2016 Mar; 471(4):596-602. PubMed ID: 26876573 [TBL] [Abstract][Full Text] [Related]
13. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers. Bellone S; McNamara B; Mutlu L; Demirkiran C; Hartwich TMP; Harold J; Yang-Hartwich Y; Siegel ER; Santin AD Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240216 [TBL] [Abstract][Full Text] [Related]
14. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study. Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313 [TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801 [TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. Hou JY; Chapman JS; Kalashnikova E; Pierson W; Smith-McCune K; Pineda G; Vattakalam RM; Ross A; Mills M; Suarez CJ; Davis T; Edwards R; Boisen M; Sawyer S; Wu HT; Dashner S; Aushev VN; George GV; Malhotra M; Zimmermann B; Sethi H; ElNaggar AC; Aleshin A; Ford JM Gynecol Oncol; 2022 Nov; 167(2):334-341. PubMed ID: 36117009 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma. Wang X; Yu N; Cheng G; Zhang T; Wang J; Deng L; Li J; Zhao X; Xu Y; Yang P; Bai N; Li Y; Bi N Clin Transl Med; 2022 Nov; 12(11):e1116. PubMed ID: 36437506 [TBL] [Abstract][Full Text] [Related]
19. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783 [TBL] [Abstract][Full Text] [Related]
20. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer. Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]